This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.
Men and women age 18-75;
Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);
Hair pulling daily with urges to pull as the trigger in >50% of the episodes of pulling;
Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;
Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);
Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;
History of seizures;
Myocardial infarction within 6 months;
Single group
Semaglutide
DrugAll participants in the study will receive semaglutide (Wegovy).
NIMH Trichotillomania Severity Scale
Clinician-rated scale assessing trichotillomania symptom severity over the past week that will be administered at all visits. Total scores range from 0-20. Higher scores indicate greater severity.
Clinical Global Impression-Improvement and Severity Scales
Clinician-administered scale consisting of two reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The CGI-S will be used at screening and the CGI-I will be used at every visit after screening. the CGI-S ranges from 1 = "not ill at all" to 7 = "among the most extremely ill." The CGI-I scale ranges from 1 = "very much improved" to 7 = "very much worse."
Massachusetts General Hospital Hair Pulling Scale
A 7-item self-report measure assessing trichotillomania severity over the past week. Total scores range from 0-28. Greater scores indicate worse symptoms.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
